Every material Form 8-K Olema Pharmaceuticals, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Olema Pharmaceuticals director Dr. Gorjan Hrustanovic resigned from the board effective October 14, 2026, and from the Compensation and Science and Technology committees. The company said the resignation was not due to any disagreement over its operations, policies or practices. On October 15, 2026, the board appointed Dr. Prakash Raman to the Compensation and Science and Technology committees.
Dr. Gorjan Hrustanovic gave notice on October 12, 2026 and resigned from the board effective October 14, 2026
He also left the Compensation Committee and the Science and Technology Committee
The company said the resignation involved no disagreement on operations, policies or practices
Dr. Prakash Raman was appointed to the Compensation and Science and Technology committees effective October 15, 2026
Olema Pharmaceuticals announced on August 13, 2026 that Jason O'Byrne has been appointed Chief Financial Officer, principal financial officer and principal accounting officer, effective August 11, 2026. He most recently served as Executive Vice President and Chief Financial Officer of Vir Biotechnology from October 2024 to August 2026. The filing sets his pay, including a $545,000 initial base salary and an option for 650,000 shares that is subject to Board approval.
Initial annualized base salary of $545,000 and an annual bonus target of 45% of base salary
Sign-on bonuses of $250,000 (within 30 days of the effective date) and $100,000 (within 30 days after the first anniversary), subject to service-based repayment
Option for 650,000 common shares under the 2022 Inducement Plan, vesting over four years, subject to Board approval
Severance includes 12 months of base salary; double-trigger protection applies if termination occurs within 3 months before or 18 months after a Change in Control
Olema Pharmaceuticals reported a second-quarter 2026 net loss of $63.2 million, up from $43.8 million a year earlier, as spending rose on late-stage clinical trials and corporate costs. The statement of operations shows no revenue line, and the company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities. The company now expects top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027.
Net loss was $63.2 million, or $0.61 per share, versus $43.8 million, or $0.51 per share, in the second quarter of 2025.
GAAP R&D expenses rose to $57.8 million from $43.9 million; G&A expenses rose to $9.4 million from $4.0 million.
Cash, cash equivalents, and marketable securities were $461.1 million as of June 30, 2026.
Enrollment in the pivotal Phase 3 OPERA-01 trial is complete; top-line data are expected in Q1 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Olema Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →